M Llewelyn, E Barbon, G Bassett, L Bennett, A Bexley… - sussex.figshare.com
Background Many patients with COVID-19 have been treated with plasma containing anti- SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent …
❚ ABSTRACT The objective of this study was to highlight the global scientific effort to fight the SARS-CoV-2, addressing the preliminary results of passive immunization through …
P Cacilhas, E Caberlon, L Angoleri… - Brazilian Journal of …, 2022 - SciELO Brasil
Convalescent plasma therapy has shown controversial results in coronavirus disease-19 (COVID-19) patients. We performed a non-randomized case-control study with …
abstract Background: Randomized trials are generally performed from a frequentist perspective, which can conflate absence of evidence with evidence of absence. The …
Abstract John S. Daniels, MD Retiring Internal Medicine Missouri Medicine Editorial Board Member, St. Louis Use of Convalescent Plasma in the Management of COVID-19 The …
W Alhazzani, R Jaeschke - Saudi Journal of Medicine & Medical …, 2021 - journals.lww.com
In this issue of the Saudi Journal of Medicine and Medical Sciences, AlShehry et al. report the interim findings of a phase II trial that describes the outcomes of 40 hospitalized adults …
JM Sturek, S Heysell, LG Lum, T Thomas, C Sheppard… - cdn.clinicaltrials.gov
Background: There are currently no proven treatment options for Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) …
Background Treatment of COVID-19 patients with plasma containing anti-SARS-CoV-2 antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate the …
H Schrezenmeier, V de Angelis, S Bégué, L Cannata… - bioengineer.org
On December 7 th, WHO updated its living guideline on COVID-19 therapeutics, including convalescent plasma (CCP). This led to their recommendation against the use of CCP for …